Literature DB >> 2836515

Generation of human cytomegalovirus-specific cytotoxic T-lymphocytes in a short-term culture.

A Laubscher1, H G Bluestein, S A Spector, N J Zvaifler.   

Abstract

A method to generate human cytomegalovirus (HCMV)-specific CTL (cytotoxic T lymphocytes) from human peripheral blood mononuclear cells is described. This assay is unique in comparison with other methods reported to date, because it only requires a short-term (6 days) coculture of PBM and autologous infected fibroblasts without the addition of exogenous IL-2 (interleukin-2) and nevertheless is sensitive enough to determine HCMV-specific killing in a short (6 h) 51Cr-release assay using autologous HCMV-infected fibroblasts as targets. The virus-specific killing is mediated by CTL of the CD8 phenotype and it can be inhibited by a HLA class I monoclonal antibody. The sensitivity of the assay can be significantly enhanced by pretreating the targets with interferon-gamma (IFN-gamma) prior to infection with HCMV. HCMV-specific 51Cr-release is more than doubled when the IFN-gamma pretreated targets are used. This increase is mostly due to enhanced sensitivity of the fibroblasts to killing mediated by CD8-positive CTL, but some killing can be attributed to CTL of the CD4 phenotype.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2836515     DOI: 10.1016/0022-1759(88)90084-1

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

1.  Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus.

Authors:  M J Gilbert; S R Riddell; C R Li; P D Greenberg
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

2.  Antigenic polymorphism of human very late activation protein-2 (platelet glycoprotein Ia-IIa). Platelet alloantigen Hca.

Authors:  V L Woods; K D Pischel; E D Avery; H G Bluestein
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

Review 3.  Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects.

Authors:  Paul Shafer; Lauren M Kelly; Valentina Hoyos
Journal:  Front Immunol       Date:  2022-03-03       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.